AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 10.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: Morningstar · NBC Boston · TradingView · Yahoo Finance · BioPharma Dive · FirstWord Pharma · Fierce Biotech · statnews.com.
How this dossier is built: methodology · AI policy · corrections.
📍 Where it landed
AbbVie announced its acquisition of Apogee Therapeutics for $10.9 billion. The deal aimed to strengthen AbbVie's immunology portfolio, with a focus on long-acting autoimmune drugs.
Epilogue added 66d ago, after coverage quieted.
The reporting (12)
- Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders Morningstar · 69d ago
- AbbVie paying $10.9B to buy Waltham biotech NBC Boston · 69d ago
- ABBV: Acquisition adds high-value immunology assets with blockbuster potential and long-term growth prospects TradingView · 69d ago
- AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion Yahoo Finance · 69d ago
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs BioPharma Dive · 69d ago
- Done deal: AbbVie to buy Apogee for $10.9B FirstWord Pharma · 69d ago
- AbbVie to acquire Apogee Therapeutics in $10.9B deal Yahoo Finance · 69d ago
- AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect Fierce Biotech · 69d ago
- AbbVie to buy Apogee Therapeutics in nearly $11B deal statnews.com · 69d ago
- AbbVie makes $10.9B move for Apogee’s long-acting I&I drug candidates Endpoints News · 69d ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 69d ago
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio AbbVie News Center · 69d ago
The story so far
AbbVie has entered into an agreement to acquire Apogee Therapeutics for $10.9 billion. The deal is designed to integrate Apogee's long-acting immunology and inflammation (I&I) drug candidates into AbbVie's existing portfolio.
Coverage from the WSJ, Stat News, and Fierce Biotech emphasizes the deal's valuation and AbbVie's interest in a specific eczema prospect described as "hotly tipped." The transaction was also confirmed via the AbbVie News Center and Endpoints News. Future developments will center on the integration of Apogee's drug candidates and the progress of the eczema prospect.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 69d ago.
The obvious questions
How much is AbbVie paying for Apogee Therapeutics?
The acquisition is valued at $10.9 billion.
What specific therapeutic area is the target of this acquisition?
The deal focuses on immunology and inflammation (I&I), specifically long-acting drug candidates and an eczema prospect.
Which outlets reported on this deal?
The acquisition was reported by the WSJ, Stat News, Fierce Biotech, Endpoints News, and the AbbVie News Center.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Open-weight AI companies are the Valley’s hottest acquisition targets
Nvidia’s rumored $12.9 billion bid catapults open‑weight AI firms into the Valley’s hottest acquisition spotlight
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The FDA has approved Gilead’s Bixlenvo, a once-daily pill designed to simplify HIV treatment for some patients.
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
Millions of Medicare patients with qualifying diagnoses are excluded from a new GLP-1 discount program.
Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
A $1.5 billion China‑U.S. biotech pact puts American VCs and Haisco at the center of a new inflammatory‑disease platform.
Shell draws Exxon interest in $8bn US chemical assets sale
Exxon and LyondellBasell are competing to buy Shell's US chemical assets, valued at up to $8 billion.
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.
Eli Lilly's new weight-loss pill Foundayo is now available in the U.K., marking a significant milestone in the pharmaceutical industry.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.